UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number 001-15170 GSK plc (Translation of registrant's name into English) 980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40 ...

GSK plc (GSK) reported core earnings of $1.09 per American depositary share (“ADS”) in first- quarter 2024, beating the Zacks Consensus Estimate of 94 cents. Core earnings rose 16% year over year on a reported basis and 28% at a constant exchange rate (CER).Quarterly revenues increased 6% on a reported basis and 10% at CER to $9.34 billion (£7.36 billion), beating the Zacks Consensus Estimate of $8.98 billion. The upside can be attributed to rising HIV and vaccine product sales, which was partially offset b ...

GSK (GSK) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.90 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.96%. A quarter ago, it was expected that this drug developer would post earnings of $0.76 per share when it actually produced earnings of $0.72, delivering a surprise of -5.26%.Over the last four quarters, the company has su ...

GSK季度业绩预测 - GSK将在2024年3月结束的季度公布业绩，预计收入增长将带来盈利的同比增长[1] - 预计5月1日发布的财报中，如果关键数据超过预期，股价可能会上涨，反之则可能下跌[2] - 分析师们对GSK的季度盈利预期为每股0.94美元，同比增长4.4%，预计营收为89.8亿美元，同比增长6.3%[4] - 分析师们在过去30天内将本季度的每股盈利预期上调了0.49%[5] GSK盈利预估 - Zacks Earnings ESP模型比较了最准确的预估值和Zacks共识预估值，正值表明盈利可能超出预期[8] - GSK的最准确预估值低于Zacks共识预估值，导致盈利预期为-3.21%，但股票目前持有Zacks排名3[12] - 过去四个季度中，GSK有三次超出共识每股盈利预期[14] 投资决策建议 - 盈利超出或不及预期并不是股价上涨或下跌的唯一依据，其他因素也会影响投资者的决策[15] - 在公司发布季度报告前，检查其盈利ESP和Zacks排名是值得的[16] - 尽管GSK不太可能在盈利方面表现出色，但投资者应该关注其他因素，以决定是否投资或远离该股[17]

GSK (GSK) closed the most recent trading day at $39.75, moving +1.22% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.88%. Elsewhere, the Dow saw an upswing of 0.56%, while the tech-heavy Nasdaq depreciated by 2.05%.Heading into today, shares of the drug developer had lost 7.32% over the past month, lagging the Medical sector's loss of 6.4% and the S&P 500's loss of 2.57% in that time.The investment community will be closely monitoring the performance of GSK ...

文章核心观点 - Zacks Premium是一个帮助投资者更自信地投资的研究服务,提供Zacks Rank和Zacks Industry Rank、Zacks 1 Rank List、Equity Research报告和Premium股票筛选等 [1][2] - Zacks Style Scores是一个独特的评分系统,根据价值、成长和动量三大投资风格对股票进行评分,帮助投资者选择最有可能战胜市场的股票 [3][4] - Zacks Rank是一个专有的股票评级模型,利用盈利预期修正来帮助投资者构建成功的投资组合 [9][10] - 投资者应该选择同时拥有Zacks Rank 1或2以及A或B级Zacks Style Scores的股票,以获得最大收益潜力 [12][14] 价值评分 - 价值投资者关注的是以合理价格买入优质股票,价值评分考察市盈率、市盈率/增长比率、市销率、市现率等多个估值指标 [5] 成长评分 - 成长型投资者关注公司的财务实力和健康状况以及未来前景,成长评分考察预期和历史的收益、销售和现金流等指标 [6] 动量评分 - 动量投资者利用股价或盈利预期的上升或下降趋势获利,动量评分考察一周股价变化和月度盈利预测变化等指标 [7] VGM评分 - VGM评分综合了价值、成长和动量三大评分,是一个全面的指标,有助于识别最具吸引力的股票 [8] 案例分析-GSK - GSK是一家拥有专科药品、疫苗和常规药品三大业务的公司 [15] - GSK目前的Zacks Rank为3(Hold),VGM评分为A,价值评分也为A,估值指标如市盈率较低 [15][16] - 过去60天内有两家分析师上调了GSK 2024财年的盈利预测,预测数据也有7.6%的平均超预期 [17] - 综合Zacks Rank和顶级的价值及VGM评分,GSK是值得关注的投资标的 [17]

GSK plc (GSK) announced that the FDA has accepted its biologics license application (BLA) seeking approval of its 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY. The FDA has granted a standard review to the BLA and is expected to give its decision on Feb 14, 2025.The MenABCWY vaccine candidate combines the antigenic components of GSK’s two popular licensed meningococcal vaccines, Bexsero (MenB) and Menveo (MenACWY). The MenABCWY combination targets the five serogroups of the bacteria Neisseria menin ...

GSK股价表现 - GSK股价在最新交易日收盘价为$40.80，较前一日上涨了+0.27%[1] - 分析显示，GSK股票在过去一个月中下跌了6.16%，落后于医疗行业的4.72%损失和标普500指数的0.8%涨幅[2] GSK财务预测 - 分析师预计GSK将于2024年5月1日发布财报，预计每股收益为$0.94，同比增长4.44%，营收预计为$8.99亿，同比增长6.47%[3] - Zacks Consensus Estimates预测GSK整个财年的每股收益为$4.03，营收为$398.9亿，分别较上一年增长了+4.4%和+5.67%[4]

The latest trading session saw GSK (GSK) ending at $41.19, denoting a +0.81% adjustment from its last day's close. The stock lagged the S&P 500's daily gain of 1.11%. Meanwhile, the Dow gained 0.8%, and the Nasdaq, a tech-heavy index, added 1.24%.Shares of the drug developer witnessed a loss of 6.24% over the previous month, trailing the performance of the Medical sector with its loss of 2.46% and the S&P 500's gain of 0.48%.The investment community will be paying close attention to the earnings performance ...

GSK (GSK) closed the most recent trading day at $41.79, moving -1.49% from the previous trading session. This change lagged the S&P 500's 0.72% loss on the day. Elsewhere, the Dow lost 1%, while the tech-heavy Nasdaq lost 0.95%.Prior to today's trading, shares of the drug developer had lost 0.05% over the past month. This has lagged the Medical sector's loss of 0.03% and the S&P 500's gain of 2.16% in that time.Market participants will be closely following the financial results of GSK in its upcoming releas ...